Last reviewed · How we verify
Terconazole Vaginal Suppository
Terconazole inhibits fungal cell membrane synthesis by blocking lanosterol 14α-demethylase, disrupting ergosterol production in Candida species.
Terconazole inhibits fungal cell membrane synthesis by blocking lanosterol 14α-demethylase, disrupting ergosterol production in Candida species. Used for Vulvovaginal candidiasis (yeast infection).
At a glance
| Generic name | Terconazole Vaginal Suppository |
|---|---|
| Also known as | Tekangzuo Yindao Shuan |
| Sponsor | Hatem AbuHashim |
| Drug class | Azole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Terconazole is an azole antifungal that selectively inhibits the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungal cells. This blocks the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting membrane instability and leakage of cellular contents leads to fungal cell death, making it effective against vaginal candidiasis.
Approved indications
- Vulvovaginal candidiasis (yeast infection)
Common side effects
- Vulvovaginal irritation or burning
- Headache
- Abdominal pain or cramping
- Vulvovaginal pruritus
Key clinical trials
- Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis (NA)
- Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis (PHASE4)
- Comparison of Boric Acid vs. Terconazole in Treatment of RVVC (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terconazole Vaginal Suppository CI brief — competitive landscape report
- Terconazole Vaginal Suppository updates RSS · CI watch RSS
- Hatem AbuHashim portfolio CI